Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 1:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 598 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Complex Patients Clear all

Conditions: Complex Regional Pain Syndrome
Interventions: Botox + Lidocaine, Lidocaine alone; Drug
Lead sponsor: VA Connecticut Healthcare System; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Drug Resistant Partial Onset Seizure
Interventions: ganaxolone; Drug
Lead sponsor: Marinus Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Santa Monica, California • Lexington, Kentucky • Golden Valley, Minnesota + 2 more

Conditions: Epilepsy, Tuberous Sclerosis Complex
Interventions: Everolimus; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 2 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 2
States / cities: Cincinnati, Ohio • Houston, Texas

Conditions: Sarcoma
Interventions: vitespen; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: New York, New York

Conditions: AIDS Dementia Complex, HIV Infections
Interventions: Abacavir sulfate; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 7
States / cities: San Diego, California • San Francisco, California • Baltimore, Maryland + 3 more

Conditions: Seizures
Interventions: Retigabine, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 539 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 2
States / cities: Bethesda, Maryland • Dallas, Texas

Conditions: Cancer
Interventions: graft versus host disease prophylaxis/therapy, allogeneic bone marrow transplantation; Biological · Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: Up to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2004
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Complex Abdominal Aortic Aneurysm
Interventions: Fenerated AAA Endovascular Graft with H&L-B One Shot Introduction System; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 70 Years to 70 Years · Male only
U.S. locations: 1
States / cities: New York, New York

Conditions: Childhood Astrocytoma, Childhood Atypical Teratoid/Rhabdoid Tumor, Diffuse Intrinsic Pontine Glioma, Glioma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Neoplasm, Recurrent Childhood Glioblastoma, Recurrent Childhood Medulloblastoma, Recurrent Primitive Neuroectodermal Tumor, Refractory Brain Neoplasm
Interventions: Laboratory Biomarker Analysis, Sargramostim, Wild-type Reovirus; Other · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 10 Years to 21 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Melanoma
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Nab-paclitaxel/Danburstotug Complex AP160; Procedure · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: ABT-751; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Up to 18 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 3
States / cities: Chicago, Illinois • Bethesda, Maryland • Philadelphia, Pennsylvania

Conditions: TSC1, TSC2, Tuberous Sclerosis Complex, MTOR
Interventions: Everolimus; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: HIV Infections
Interventions: Zidovudine, Zalcitabine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 528 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 24
States / cities: Harbor City, California • Los Angeles, California • San Diego, California + 19 more

Conditions: Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Low-grade Cerebellar Astrocytoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Medulloepithelioma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Recurrent Childhood Brain Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma
Interventions: lenalidomide, perfusion-weighted magnetic resonance imaging, diffusion-weighted magnetic resonance imaging, laboratory biomarker analysis; Drug · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: HIV Infections
Interventions: Ro 24-7429, Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 4
States / cities: San Diego, California • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: Advanced Non-Small Cell Lung Cancer, Squamous Cell Carcinoma, Advanced NSCLC, Adenosquamous Carcinoma, Adenocarcinoma
Interventions: Aldesleukin, Fludarabine, Cyclophosphamide, Young TIL; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 72 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cancer
Interventions: entinostat; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 3
States / cities: Bethesda, Maryland

Conditions: Spinal Fusion, Activities of Daily Living Following Complex Spinal Fusions
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: HIV Infections
Interventions: Zidovudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: HIV Infections
Interventions: Aldesleukin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 10
States / cities: Birmingham, Alabama • Aurora, Colorado • Indianapolis, Indiana + 5 more

Conditions: Seizures, Epilepsies, Partial, Epilepsy, Complex Partial, Epilepsy, Generalized, Epilepsy
Interventions: Placebo, Vanquix Auto-Injector (Diazepam Injection); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 86
States / cities: Northport, Alabama • Little Rock, Arkansas • Irvine, California + 44 more

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: Panitumumab, Carboplatin, Paclitaxel, Intensity Modulated Radiation Therapy, 5-Fluorouracil, Docetaxel, Cisplatin; Drug · Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Sensation Disorders, Sensation, Phantom, Pain, Postoperative, Pain, Chronic, Numbness, Sensory Disorder, Sensory Defect, Phantom Pain, Phantom Sensation
Interventions: Sensory testing; Diagnostic Test
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2033
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: HIV Infections
Interventions: Zidovudine, Foscarnet sodium; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1991
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Chapel Hill, North Carolina

Search by objective public record fields.

"Efficacy of Botulinum Toxin Injection in Reducing Limb Pain in Patients With Complex Regional Pain Syndrome"

A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset Seizures

Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)

Vaccine Therapy in Treating Patients With Recurrent Soft Tissue Sarcoma

A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia Complex

Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy

Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

Compassionate Use Treatment for a Single Patient With a Custom Made Branched/Fenestrated Endovascular Device for the Treatment of Complex Abdominal Aortic Aneurysm

Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors

Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors

ABT-751 in Treating Young Patients With Refractory Solid Tumors

Everolimus for Cancer With TSC1 or TSC2 Mutation

A Randomized, Open-Label Study of Alternative Treatment Combinations of Dideoxycytidine (HIVID; ddC) and Zidovudine (AZT) in Patients With HIV Infection

Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors

A Randomized Study of Activity, Safety, and Tolerance of Oral Ro 24-7429 (Tat Antagonist) in Patients With HIV Infection

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Impact of Body Habitus (Arm Span and Abdominal Girth) on Activities of Daily Living (ADL)

An Oral Dose-Ranging Finding Study in Patients With HIV Disease, CDC Classification Groups IIB, III, and IV-C2

A Phase II Study of Low-Dose Interleukin-2 by Subcutaneous Injection in Combination With Antiretroviral Therapy Versus Antiretroviral Therapy Alone in Patients With HIV-1 Infection and at Least 3 Months Stable Antiretroviral Therapy

Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.

Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck

Prospective Study of Sensation and Satisfaction in Cancer and Transgender Mastectomy Patients

A Study of Foscarnet in the Treatment of HIV Infection in Patients Who Have Taken Zidovudine for a Long Time